Quantinno Capital Management LP Acquires 15,225 Shares of BioMarin Pharmaceutical Inc. $BMRN

Quantinno Capital Management LP increased its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 41.2% in the first quarter, HoldingsChannel reports. The institutional investor owned 52,147 shares of the biotechnology company’s stock after purchasing an additional 15,225 shares during the quarter. Quantinno Capital Management LP’s holdings in BioMarin Pharmaceutical were worth $2,946,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of BMRN. Norges Bank bought a new position in BioMarin Pharmaceutical in the fourth quarter valued at approximately $447,572,000. Vestal Point Capital LP raised its position in shares of BioMarin Pharmaceutical by 261.4% during the 4th quarter. Vestal Point Capital LP now owns 3,000,000 shares of the biotechnology company’s stock valued at $178,290,000 after acquiring an additional 2,170,000 shares during the last quarter. Viking Global Investors LP lifted its stake in shares of BioMarin Pharmaceutical by 13.8% in the 2nd quarter. Viking Global Investors LP now owns 12,288,611 shares of the biotechnology company’s stock valued at $675,505,000 after purchasing an additional 1,488,552 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of BioMarin Pharmaceutical by 48.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 3,321,754 shares of the biotechnology company’s stock valued at $197,405,000 after purchasing an additional 1,076,568 shares during the period. Finally, Northwestern Mutual Wealth Management Co. boosted its position in shares of BioMarin Pharmaceutical by 3,494.9% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 957,011 shares of the biotechnology company’s stock worth $56,875,000 after purchasing an additional 930,390 shares during the last quarter. 98.71% of the stock is currently owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Price Performance

Shares of BMRN stock opened at $63.81 on Friday. The company has a quick ratio of 4.20, a current ratio of 5.81 and a debt-to-equity ratio of 0.23. BioMarin Pharmaceutical Inc. has a 12-month low of $49.26 and a 12-month high of $66.28. The firm has a fifty day moving average of $58.19 and a 200-day moving average of $57.06. The firm has a market capitalization of $12.33 billion, a price-to-earnings ratio of 172.46, a price-to-earnings-growth ratio of 0.49 and a beta of 0.24.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, topping the consensus estimate of $0.95 by $0.25. The business had revenue of $989.71 million for the quarter, compared to the consensus estimate of $932.03 million. BioMarin Pharmaceutical had a return on equity of 5.36% and a net margin of 2.14%.The firm’s revenue was up 20.0% compared to the same quarter last year. During the same quarter last year, the business posted $1.44 EPS. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. On average, equities research analysts forecast that BioMarin Pharmaceutical Inc. will post 4.22 earnings per share for the current year.

Key Stories Impacting BioMarin Pharmaceutical

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Q2 results exceeded expectations. BioMarin reported adjusted earnings of $1.20 per share versus the $0.95–$0.96 analyst consensus, while revenue rose 20% year over year to approximately $990 million, ahead of estimates near $932 million. BioMarin Surpasses Q2 Earnings and Revenue Estimates
• Positive Sentiment: Management raised its 2026 outlook. Full-year adjusted EPS guidance increased to $4.90-$5.10 from a prior level below that range and above the roughly $4.80 consensus. Revenue guidance was set around $3.9 billion. Stronger-than-expected VOXZOGO sales and continued momentum in key therapies supported the revision. BioMarin Reports Second Quarter 2026 Results
• Positive Sentiment: Amicus additions could improve long-term growth. BioMarin said the addition of GALAFOLD and POMBILITI plus OPFOLDA, along with cost synergies, should accelerate revenue growth, earnings accretion, operating-margin expansion and cash flow through the mid-2030s. BioMarin Lifts 2026 Outlook
• Positive Sentiment: Morgan Stanley raised its price target to $124 from $119 and maintained an Overweight rating, signaling substantial potential upside in its valuation view.
• Neutral Sentiment: HC Wainwright increased its target to $60 from $50 but retained a Neutral rating, indicating more cautious expectations than Morgan Stanley.
• Negative Sentiment: BioMarin discontinued a $270 million rare-disease asset after the treatment missed its Phase 3 endpoint. The setback removes a potential growth opportunity and highlights clinical-development risk. BioMarin Axes Rare-Disease Asset

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on BMRN shares. Morgan Stanley upped their price objective on BioMarin Pharmaceutical from $119.00 to $124.00 and gave the company an “overweight” rating in a report on Friday. Weiss Ratings upgraded BioMarin Pharmaceutical from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, June 26th. Bank of America decreased their target price on BioMarin Pharmaceutical from $85.00 to $80.00 and set a “buy” rating for the company in a research report on Tuesday, May 19th. Oppenheimer upped their price target on BioMarin Pharmaceutical from $95.00 to $97.00 and gave the company an “outperform” rating in a research note on Friday. Finally, UBS Group reiterated a “neutral” rating on shares of BioMarin Pharmaceutical in a research report on Tuesday, July 14th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $87.86.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.